The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook

References

• Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157:9–25 e12.
   PubMed Web of Science ®Google Scholar
• Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379:1739–1748.
   PubMed Web of Science ®Google Scholar
• Curtin BJ. Physiologic vs pathologic myopia: genetics vs environment. Ophthalmology. 1979;86:681–691.
   PubMed Web of Science ®Google Scholar
• Montero JA, Ruiz-Moreno JM. Treatment of choroidal neovascularization in high myopia. Curr Drug Targets. 2010;11:630–644.
   PubMed Web of Science ®Google Scholar
• Wong TY, Ohno-Matsui K, Leveziel N, et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol. 2015;99:289–296.
   PubMed Web of Science ®Google Scholar
• Bovey EH, Gonvers M. Transscleral diathermy: an additional tool in the management of retinal detachment due to posterior breaks in highly myopic eyes. Retina. 1999;19:489–494.
   PubMed Web of Science ®Google Scholar
• Ozdek S, Hondur A, Gurelik G, et al. Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. Int Ophthalmol. 2005;26:127–133.
   PubMedGoogle Scholar
• Neelam K, Cheung CMG, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31:495–525.
   PubMed Web of Science ®Google Scholar
• Mitry D, Zambarakji H. Recent trends in the management of maculopathy secondary to pathological myopia. Graefes Arch Clin Exp Ophthalmol. 2012;250:3–13.
   PubMed Web of Science ®Google Scholar
• Jalkh AE, Weiter JJ, Trempe CL, et al. Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic Surg. 1987;18:721–725.
   PubMedGoogle Scholar
• Secretan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7:307–316.
   PubMedGoogle Scholar
• Zhang Y, Han Q, Ru Y, et al. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application. Drug Des Devel Ther. 2015;9:3413–3421.
   PubMed Web of Science ®Google Scholar
• Sakimoto S, Sakaguchi H, Ohji M, et al. Consecutive case series with long-term follow-up of full macular translocation for myopic choroidal neovascularisation. Br J Ophthalmol. 2014;98:1221–1225.
   PubMed Web of Science ®Google Scholar
• Chan WM, Ohji M, Lai TY, et al. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol. 2005;89:1522–1528.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol. 2001;85:1041–1043.
   PubMed Web of Science ®Google Scholar
• Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol. 2000;118:344–350.
   PubMedGoogle Scholar
• Kobayashi H, Kobayashi K. Radiotherapy for subfoveal neovascularisation associated with pathological myopia: a pilot study. Br J Ophthalmol. 2000;84:761–766.
   PubMed Web of Science ®Google Scholar
• Costa RA, Calucci D, Teixeira LF, et al. Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol. 2003;135:857–866.
   PubMed Web of Science ®Google Scholar
• Lee YA, Ho TC, Chen MS, et al. Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization. Eye (Lond). 2009;23:645–651. doi:10.1038/eye.2008.17.
   PubMed Web of Science ®Google Scholar
• Costa RA, Williams GA. Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia: results from a randomized pilot study. Retina. 2006;26:757–764. doi:10.1097/01.iae.0000244260.52901.2e.
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial–VIP report no. 1. Ophthalmology. 2001;108:841–852.
   PubMed Web of Science ®Google Scholar
• Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial–VIP report no. 3. Ophthalmology. 2003;110:667–673.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol. 2010;128:437–442.
   PubMed Web of Science ®Google Scholar
• Pece A, Isola V, Vadala M, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study. Retina. 2006;26:746–751.
   PubMed Web of Science ®Google Scholar
• Schnurrbusch UEK, Jochmann C, Wiedemann P, et al. Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2005;243:829–833.
   PubMed Web of Science ®Google Scholar
• Visodyne. verteporfin [cited 2015 Nov 18]. Available from: www.novartis.com.au/PI_PDF/vid.pdf.
   Google Scholar
• Wong TY, Foster PJ, Hee J, et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest Ophthalmol Vis Sci. 2000;41:2486–2494.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina. 1992;12:127–133.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110:1297–1305.
   PubMed Web of Science ®Google Scholar
• Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology. 1999;106:2063–2067.
   PubMed Web of Science ®Google Scholar
• Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment–TAP and VIP report No. 2. Arch Ophthalmol. 2003;121:1253–1268.
   PubMedGoogle Scholar
• Leveziel N, Caillaux V, Bastuji-Garin S, et al. Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am J Ophthalmol. 2013;155:913–919.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Sayanagi K, Soga K, et al. Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina. 2008;28:1124–1131.
   PubMed Web of Science ®Google Scholar
• Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol. 2008;53:121–138.
   PubMed Web of Science ®Google Scholar
• Keane PA, Liakopoulos S, Chang KT, et al. Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol. 2008;92:1081–1085.
   PubMed Web of Science ®Google Scholar
• Kang HM, Koh HJ. Lack of polypoidal lesions in patients with myopic choroidal neovascularization as evaluated by indocyanine green angiography. Am J Ophthalmol. 2014;157:378–383 e1.
   PubMed Web of Science ®Google Scholar
• Sayanagi K, Ikuno Y, Soga K, et al. Choroidal vascular hypofluorescence in indocyanine green angiography of high myopia. Br J Ophthalmol. 2009;93:1687–1690.
   PubMed Web of Science ®Google Scholar
• Farinha CL, Baltar AS, Nunes SG, et al. Progression of myopic maculopathy after treatment of choroidal neovascularization. Ophthalmologica. 2014;231:211–220.
   PubMed Web of Science ®Google Scholar
• Chang L, Pan CW, Ohno-Matsui K, et al. Myopia-related fundus changes in Singapore adults with high myopia. Am J Ophthalmol. 2013;155:991–999 e1.
   PubMed Web of Science ®Google Scholar
• Axer-Siegel R, Cotlear D, Priel E, et al. Indocyanine green angiography in high myopia. Ophthalmic Surg Lasers Imaging. 2004;35:139–145.
   PubMedGoogle Scholar
• Battaglia Parodi M, Iacono P, Bandello F. Correspondence of leakage on fluorescein angiography and optical coherence tomography parameters in diagnosis and monitoring of myopic choroidal neovascularization treated with bevacizumab. Retina. 2016;36:104–109.
   Google Scholar
• Chhablani J, Deepa MJ, Tyagi M, et al. Fluorescein angiography and optical coherence tomography in myopic choroidal neovascularization. Eye (Lond). 2015;29:519–524.
   PubMed Web of Science ®Google Scholar
• Quaranta M, Arnold J, Coscas G, et al. Indocyanine green angiographic features of pathologic myopia. Am J Ophthalmol. 1996;122:663–671.
   PubMed Web of Science ®Google Scholar
• Introini U, Casalino G, Querques G, et al. Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye (Lond). 2012;26:976–982.
   PubMed Web of Science ®Google Scholar
• Jiang C, Wang W, Xu G, et al. Retinoschisis at macular area in highly myopic eye by optic coherence tomography. Yan Ke Xue Bao. 2006;22:190–194.
   PubMedGoogle Scholar
• Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol. 2002;12:117–122.
   PubMed Web of Science ®Google Scholar
• Varano M, Iacono P, Giorno P, et al. Photodynamic therapy in subfoveal and juxtafoveal myopic choroidal neovascularization: a 10-year retrospective analysis. Ophthalmologica. 2014;231:204–210.
   PubMed Web of Science ®Google Scholar
• Tan CS, Chew MC, Lim TH. Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization. Eye (Lond). 2014;28:17–22.
   PubMed Web of Science ®Google Scholar
• Schnurrbusch UEK, Jochmann C, Einbock W, et al. Complications after photodynamic therapy. Arch Ophthalmol. 2005;123:1347–1350.
   PubMedGoogle Scholar
• Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol. 2004;138:434–438.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Nagai Y, Matsuda S, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol. 2010;149:140–146.
   PubMed Web of Science ®Google Scholar
• Zhou L, Xing YQ, Li T, et al. Meta-analysis of best corrected visual acuity after treatment for myopic choroidal neovascularisation. Int J Ophthalmol. 2014;7:720–725.
   PubMed Web of Science ®Google Scholar
• Parravano M, Ricci F, Oddone F, et al. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization. Retina. 2014;34:2053–2062.
   PubMed Web of Science ®Google Scholar
• Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574–584.
   PubMed Web of Science ®Google Scholar
• Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905–909.
   PubMed Web of Science ®Google Scholar
• Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219–1224.
   PubMed Web of Science ®Google Scholar
• Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143–152.
   PubMed Web of Science ®Google Scholar
• FDA Approves New Drug Treatment for Age-Related Macular Degeneration [cited 2015 Nov 17]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/2004/ucm108385htm.
   Google Scholar
• Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141:456–462.
   PubMed Web of Science ®Google Scholar
• Kitagawa T, Yuzawa M. [Intravitreal pegaptanib sodium for myopic choroidal neovascularization: 1 year results of a prospective pilot study]. Nippon Ganka Gakkai Zasshi. 2013;117:344–350.
   PubMedGoogle Scholar
• Rinaldi M, Chiosi F, Dell’Omo R, et al. Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study. Retina. 2013;33:397–402.
   PubMed Web of Science ®Google Scholar
• Liang IC, Chang YY, Lee TS, et al. Treatment of myopic choroidal neovascularization with posterior sub-Tenon’s bevacizumab injection (Avastin (R)). Int Ophthalmol. 2014;34:971–977.
   PubMedGoogle Scholar
• Sarao V, Veritti D, Macor S, et al. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. Graefes Arch Clin Exp Ophthalmol. 2015. PMID: 26084446.
   PubMed Web of Science ®Google Scholar
• Peiretti E, Vinci M, Fossarello M. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol. 2012;47:28–33.
   PubMed Web of Science ®Google Scholar
• Voykov B, Gelisken F, Inhoffen W, et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol. 2010;248:543–550.
   PubMed Web of Science ®Google Scholar
• Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121:682–692 e2.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology. 2015;122:1220–1227.
   PubMed Web of Science ®Google Scholar
• Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120:1944–1945 e1.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Arias L, Montero JA, et al. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol. 2013;97:1447–1450.
   PubMed Web of Science ®Google Scholar
• Yang X, Dai H. Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients. Chin Med J (Engl). 2014;127:2906–2910.
   PubMed Web of Science ®Google Scholar
• Kung YH, Wu TT, Huang YH. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol. 2014;92:e615–620.
   PubMed Web of Science ®Google Scholar
• Lai TY, Luk FO, Lee GK, et al. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012;26:1004–1011.
   PubMed Web of Science ®Google Scholar
• Cha DM, Kim TW, Heo JW, et al. Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study. BMC Ophthalmol. 2014;14:69.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96:1157–1158.
   PubMed Web of Science ®Google Scholar
• Browning DJ, Kaiser PK, Rosenfeld PJ, et al. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012;154:222–226.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548.
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Ikuno Y, Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina. 2011;31:880–886.
   PubMed Web of Science ®Google Scholar
• Iacono P, Parodi MB, Papayannis A, et al. A new treatment algorithm for the management of myopic choroidal neovascularization using intravitreal ranibizumab. Acta Ophthalmol. 2015;93:e519–520.
   PubMed Web of Science ®Google Scholar
• Yang HS, Kim JG, Kim JT, et al. Prognostic factors of eyes with naive subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol. 2013;156:1201–1210 e2.
   PubMed Web of Science ®Google Scholar
• Ng DS-C, Kwok AKH, Tong JM-K, et al. Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. Retina. 2015;35:2457–2468.
   PubMedGoogle Scholar
• Wang J, Kang Z. Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol. 2012;250:1717–1723.
   PubMed Web of Science ®Google Scholar
• Miyake M, Yamashiro K, Akagi-Kurashige Y, et al. Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia. Ophthalmology. 2014;121:225–233.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Sacconi R, et al. Fundus autofluorescence changes after ranibizumab treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Am J Ophthalmol. 2015;160:322–327 e2.
   PubMed Web of Science ®Google Scholar
• Freund KB, Hoang QV, Saroj N, et al. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015;122:1802–1810.
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–161.
   PubMed Web of Science ®Google Scholar
• Sarks J, Tang K, Killingsworth M, et al. Development of atrophy of the retinal pigment epithelium around disciform scars. Br J Ophthalmol. 2006;90:442–446.
   PubMed Web of Science ®Google Scholar
• Ford KM, Saint-Geniez M, Walshe T, et al. Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2011;52:9478–9487.
   PubMed Web of Science ®Google Scholar
• Huang J, Chen T, Lu Y, et al. Retinoschisis and intravitreal ranibizumab treatment for myopic choroidal neovascularization. Chin Med J (Engl). 2014;127:2053–2057.
   PubMed Web of Science ®Google Scholar
• Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina. 2010;30:418–424.
   PubMed Web of Science ®Google Scholar
• Boyer D. A Phase 2b Study of Fovista™, a Platelet Derived Growth Factor (PDGF) inhibitor in combination with a Vascular Endothelial Growth Factor (VEGF) inhibitor for Neovascular Age-Related Macular Degeneration (AMD). Investigative Ophthalmology & Visual Science 2013; ARVO 2013 Annual Meeting; 2013 May 5–9; Seattle, WA; Vol. 54, 2175.
   Google Scholar
• Wong TP, Brown DM, Benz MS. Phase II clinical trial of intravenous combretastatin A4 phosphate in patients with subfoveal choroidal neovascular membranes (CNV) in pathologic myopia. Investigative Ophthalmology & Visual Science 2007; Association for Research in Vision and Ophthalmology (ARVO) 2007 annual meeting; May 6-10; Fort Lauderdale, FL; Vol. 48, 1457.
   Google Scholar
• Safety and efficacy study of combretastatin A4 phosphate to treat patients with choroidal neovascularization secondary to pathologic myopia [cited 2015 Nov 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01423149.
   Google Scholar
• Research with retinal cells derived from stem cells for myopic macular degeneration [cited 2015 Nov 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02122159.
   Google Scholar
• Yu L, Li ZK, Gao JR, et al. Epidemiology, genetics and treatments for myopia. Int J Ophthalmol. 2011;4:658–669.
   PubMed Web of Science ®Google Scholar
• Jacobi FK, Pusch CM. A decade in search of myopia genes. Front Biosci (Landmark Ed). 2010;15:359–372.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201.
   PubMed Web of Science ®Google Scholar
• Iacono P, Parodi MB, Papayannis A, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina. 2012;32:1539–1546.
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina. 2008;28:1308–1313.
   PubMed Web of Science ®Google Scholar
• Costagliola C, Semeraro F, Dell’omo R, et al. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation. Br J Ophthalmol. 2015;99:1004–1008.
   PubMed Web of Science ®Google Scholar